Dansk Selskab for Almen Medicin logoDansk Selskab for Almen Medicin logo
Redskabsark

Publiseret: 2025

Vægttabsmedicin

Anvendelse af vægttabsmedicin i almen praksis

Referencer

  1. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A m.fl. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 21. juni 2024;391(13):1193–1205. doi: 10.1056/NEJMoa2404881.

  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S m.fl. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 11. november 2023;389(24):2221–2232. doi: 10.1056/NEJMoa2307563.

  3. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C m.fl. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 23. marts 2021;325(14):1414–1425. doi: 10.1001/jama.2021.3224.

  4. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A m.fl. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 13. april 2021;325(14):1403–1413. doi: 10.1001/jama.2021.1831.

  5. Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I m.fl. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 18. marts 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183.

  6. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L m.fl. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 13. marts 2021;397(10278):971–984. oi: 10.1016/S0140-6736(21)00213-0.

  7. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP m.fl. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 10. oktober 2022;28(10):2083–2091. doi: 10.1038/s41591-022-02026-4.

  8. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY m.fl. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2. januar 2024;331(1):38–48. doi: 10.1001/jama.2023.24945.

  9. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G m.fl. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 15. oktober 2023;29(11):2909–2918. doi: 10.1038/s41591-023-02597-w.

  10. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B m.fl. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 21. juli 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038.

  11. Garvey WT, Frias JP, Jastreboff AM, Roux CW le, Sattar N, Aizenberg D m.fl. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 19. august 2023;402(10402):613–626. doi: 10.1016/S0140-6736(23)01200-X.

  12. Bliddal H, Bays H, Czernichow S, Hemmingsson JU, Hjelmesæth J, Morville TH m.fl. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 30. oktober 2024;391(17):1573–1583. doi: 10.1056/NEJMoa2403664.

  13. Dogan ADA, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB. Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 22. februar 2022;17:405–414. doi: 10.2147/COPD.S350133.

  14. Europæiske Union (EU). Produktresume, Mounjaro. https://ec.europa.eu/health/documents/community-register/2023/20231211161235/anx_161235_da.pdf.  https://pro.medicin.dk/Medicin/Praeparater/10641

  15. Europæiske Union (EU). Produktresume, Wegovy. https://ec.europa.eu/health/documents/community-register/2024/20240610162747/anx_162747_da.pdf. https://pro.medicin.dk/Medicin/Praeparater/10247

  16. Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP m.fl. The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. J Bone Miner Res. 1. november 2017;32(11):2278–2287. doi: 10.1002/jbmr.3214.

  17. Mountjoy M, Ackerman KE, Bailey DM, Burke LM, Constantini N, Hackney AC m.fl. 2023 International Olympic Committee’s (IOC) consensus statement on Relative Energy Deficiency in Sport (REDs). Br J Sports Med. 1. september 2023;57(17):1073-1097. doi: 10.1136/bjsports-2023-106994.